Pfizer Canada to upgrade technology in Montreal manufacturing facility
Pfizer Canada has pledged $31.7 million to its Pfizer Global Supply (PGS) Montreal manufacturing facility to upgrade technology and increase capacity to accommodate growth from new export mandates.
The project was facilitated by a contribution of $2.67 million from Investissement Québec, whose mission is to foster investment in and economic development within the province of Québec. Of the total $31.7-million investment, half of the funds were put towards purchasing new state-of-the-art equipment, while other investment funds were used to renovate the existing facilities to double its annual manufacturing capacity. The completion of the project allows the PGS Montreal site the ability to produce more than 4.4 billion tablets of multivitamins each year, enough to fill seven Olympic-sized pools.
The new equipment and facilities include a high-speed automated bottle packaging line, one additional compression machine, two additional blenders and coating machines, two new dispensing rooms and additional storage space.
“This new investment illustrates Pfizer’s continued commitment to the province of Québec. It is a tribute to the success of our colleagues at the Montreal manufacturing facility who meet the high standards of quality and efficiency that allow the site to win and maintain global manufacturing mandates,” said John Helou, president of Pfizer Canada, in a statement. “The destination of pharmaceutical investments depends on multiple factors and a world-class facility with a highly-skilled work-force is certainly a strong argument in favour of Montreal.”